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The tumor suppressor CYLD is a deubiquitinating enzyme that inhibits activation of the NF-κB, which has key roles in
inﬂammation and apoptosis. We hypothesized that CYLD may regulate the NF-κB signaling pathway in cholesteatoma. We
conducted immunohistochemistry to examine the expression of CYLD and NF-κB in 16 cases of cholesteatoma and paired cases
of retroauricular (RA) skin. In cholesteatoma epithelium, activated NF-κ B expression was signiﬁcantly higher than in RA skin,
whereasCYLDexpressionwassigniﬁcantlylowerincholesteatomaepitheliumthaninRAskin(P<. 05).Furthermore,asigniﬁcant
inverse correlation was detected between CYLD and activated NF-κB expression in cholesteatoma epithelium (r =− 0.630). We
found that CYLD reduced and activated increased NF-κB in cholesteatoma epithelium in comparison to RA skin. The inverse
correlation between CYLD and activated NF-κB in cholesteatoma may be involved in cholesteatoma epithelial hyperplasia.
1.Introduction
The growth of keratinocytes in the epidermis is regulated
by a delicate balance between molecules that control cell
survival and cell death. If this regulation is disturbed,
epithelial cells may become pathological hyperprolifera-
tive lesions, such as cholesteatoma. The molecular and
cellular processes resulting in the clinical hallmarks of
cholesteatomas(i.e.,migration, uncoordinated proliferation,
altered diﬀerentiation, and aggressiveness) are not yet fully
understood. In cholesteatoma, keratinocytic diﬀerentiation
and proliferation may be modulated by many cytokines,
transcription factors, and inﬂammatory mediators such as
TNF-α and IL-1α[1]. The tumor suppressor gene CYLD,
which was recently identiﬁed as the cylindromatosis gene,
has a deubiquitinating enzyme (DUB) activity and inhibits
activation of the transcription factor NF-κB, which has key
roles in inﬂammation, immune responses, carcinogenesis,
and protection against apoptosis [1]. In cholesteatoma,
however, the role of NF-κB has yet to be clearly deﬁned. For
example, NF-κB was reported to be found in cholesteatoma
epithelium, but it appeared to be inactivated [2]. However,
a recent report suggested that activated NF-κB plays a role
in cellular hyperplasia of cholesteatoma [3]. Generally, in
normal resting cells, NF-κB is localized within the cytoplasm
as a heterodimeric complex composed of p50 and p65
subunits bound to members of the class of inhibitory
proteins called inhibitor kappa B (IκB). After various
stimuli, the phosphorylation of IκBs, an important step in
NF-κB activation, is mediated by IκB kinase (IKK). The
IKK complex consists of at least three subunits, including
the kinases IKK-α and IKK-β and the regulatory subunit
IKK-γ. Phosphorylated IκB is then ubiquitinated, which
targets it for degradation by the 26S proteasome, thereby
releasing NF-κB dimers from the cytoplasmic NF-κB–IκB
complex and allowing them to translocate to the nucleus
and induce target gene expression [4, 5]. At this point,
CYLD binds to NF-κB essential modulator (NEMO)/IKK-γ
and appears to regulate its activity through deubiquitination
of TNF receptor-associated factor 2 (TRAF 2) [5]. CYLD
was recently reported to negatively regulate NF-κB signaling
by deubiquitination, and loss of deubiquitinating activity
of CYLD is correlated with tumorigenesis [5–7]. CYLD
also negatively regulates the c-Jun N-terminal kinase (JNK)
signaling pathway and mitogen-activated protein kinase
(MAPK) pathway, which are known to participate in a wide2 Mediators of Inﬂammation
range of cellular processes, including proliferation, diﬀeren-
tiation, and apoptosis of cholesteatoma [1, 8]. In addition,
CYLD negatively regulates RANK signaling, which is known
to be a key factor in bone resorption in cholesteatoma [9].
Therefore, investigation of CYLD expression may be a key
step to understanding the cellular survival or hyperplasia in
cholesteatoma epithelium. We hypothesized that CYLD may
be involved in the NF-κB signaling pathway and that the
inverse correlation between CYLD and activated NF-κBl e v e l
may be related to the mechanism of cellular hyperplasia in
cholesteatoma epithelium. To determine the role of CYLD
in NF-κB signaling of cholesteatoma, CYLD and NF-κB
expression levels in middle ear cholesteatoma epithelium
were examined by immunohistochemical analysis to deter-
mine protein level and localization and compared to those
of normal retroauricular (RA) skin. We also examined the
relationshipbetweenCYLDexpressionandNF-κBacti vation
in middle ear cholesteatoma.
2. Methods
2.1. Subject Selection. Tissues of acquired cholesteatoma,
diagnosed clinically and conﬁrmed pathologically after
surgery, were used in this study. All cholesteatomas extended
tothemastoid,withvaryingdegreesofatticbonedestruction
with keratin retention. The samples were obtained from
patients ranging in age from 45 to 60 years (mean age:
52 years) who had undergone middle ear surgery for
cholesteatomatous otitis media between November 2008 and
May 2009 at the Department of Otolaryngology, Kyung
Hee University East-West Neo Medical Center, Seoul, Korea.
Paired normal RA skin was obtained during ear surgery
for use as a control. Sixteen samples of cholesteatoma and
paired normal RA skin samples were obtained for this study.
The institutional review boards (IFC/IRB) of the Kyung
Hee University East-West Neo Medical Center approved the
protocol used in this study (IRB approval no. KHNMC
IRB2008-007).
2.2. Immunohistochemistry. Cholesteatoma and normal RA
skin were ﬁxed in 4% formaldehyde, dehydrated in a graded
ethanol series (70%, 95%, and 100%), and ﬁnally embedded
in paraﬃn. Paraﬃn-embedded tissues were cut into 10
μm thick sections using a paraﬃn block cutter (Thermo
Shandon,Runcorn,Cheshire,UK)andmountedonadhesive
s l i d e sc o a t e dw i t hp o l y - l-lysine (cat. no. P8920; Sigma,
St. Louis, MO). For immunohistochemistry, sections were
deparaﬃnized, rehydrated, and treated in 10mmol/L citric
acid buﬀer (pH 6.0) at 95
◦C–100
◦C for 20 minutes for anti-
gen retrieval. Endogenous peroxidase activity was blocked
by incubation in 0.5% H2O2 in methanol for 20 minutes.
Sections were then processed for immunohistochemistry
using antibodies against CYLD (1:500 dilution; Abcam
Inc., Cambridge, MA) and NF-κB (1:300 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA) overnight at 4◦C. The
ABC method was used to detect cells labeled speciﬁcally
using a Vectastain kit (Vector Laboratories, Burlingame,
CA). Diaminobenzidine (DAB) was used as a substrate
for peroxidase. The sections were subjected to a single
immunostaining by enzyme-antibody method as described
above. To conﬁrm the colocalization of CYLD and NF-κB,
two serial sections (10–20μm thickness) were subjected to
single immunostaining using each antibodie. Images were
obtained using an Olympus (Tokyo, Japan) microscope
and SPOT (Diagnostic Instruments Inc., Sterling Heights,
MI). In all immunohistochemical controls, reaction to the
substrate was absent if the primary antibody was omitted
or if the primary antibody was replaced by nonimmune
control antibody. Some sections were counterstained with
hematoxylin to visualize the epithelial cell nuclei.
2.3. Data Analysis. Three investigators blinded to the exper-
imental groups examined immunostained sections with an
image analyzer attached to a light microscope. The total
number of cells in the ﬁxed domain, the number of cells with
nuclear staining for NF-κB and CYLD-positive cells in the
epithelial layer of cholesteatoma and normal RA skin tissues,
was counted under ﬁve ×400 ﬁelds in the ﬁxed domain.
Then, both the levels of activated NF-κB( n u m b e ro fc e l l s
with nuclear staining/total number of cells counted) and
CYLD expression (number of positively stained cells/total
number of cells counted) were obtained and expressed as
percentages.
Data are expressed as means ± SD. The Mann-Whitney
test was used to compare the means of paired variables.
The level of signiﬁcance was set at P<. 05. The Pearson’s
correlation test was used to determine the association
between activated NF-κB and CYLD, with the level of
signiﬁcancesetat0.05.WealsoanalyzedactivatedNF-κBand
CYLDlevelsaccordingtotheexistenceofactiveotorrheaand
state of bony destruction using the Mann-Whitney test. The
SPSS10 software package (SPSS, Chicago, IL) was used for
the analyses.
3. Results
3.1. Immunohistochemistry of CYLD and NF-κBE x p r e s -
sion in Cholesteatoma Epithelium. The following results
were obtained by immunohistochemical analysis of 16
cholesteatoma tissues and paired normal RA skin specimens.
Immunohistochemicaldataindicatedthatimmunoreactivity
of CYLD was mainly present in the cytoplasm and per-
inuclear region of the basal layer and granular layer in
normal RA skin (Figure 1(a)). In the cholesteatoma tissue,
CYLD expression was seen in a few cells in the basal
layer (Figure 1(b)). The percentage of CYLD-positive cells
in cholesteatoma tissues was 38.48% ± 21.20% compared
to 80.95% ± 8.08% in paired normal RA skin. The per-
centage of CYLD-positive cells in cholesteatoma tissue was
signiﬁcantly lower as compared to paired normal RA skin
(P = .022).
The diﬀerential expression of NF-κBw a sf o u n db e t w e e n
normal RA skin and cholesteatoma epithelium. As shown
in Figure 2(a),N F - κB expression was seen mostly in the
cytoplasm (inactivated form) and was localized mainly in
the basal epithelial layer of normal skin. In addition, we
found some nuclear staining of NF-κB in the basal and
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Figure 1: Immunohistochemistry of CYLD in cholesteatoma epithelium and normal retroauricular (RA) skin. (a): CYLD in normal RA
skin. (b): CYLD in cholesteatoma epithelium. Note that strong CYLD immunoreactivity was observed mainly in the cytoplasm of cells in
the basal and suprabasal epithelial layers of normal RA skin, whereas weak expression was detected in the cytoplasm of cells in the basal
layer of the cholesteatoma epithelium. Bar = 300μm. (c): Rates of positive labeling for CYLD in cholesteatoma epithelium and normal RA
skin. The rate of cells positive for CYLD was signiﬁcantly lower in cholesteatoma epithelium than in normal RA skin. Data are presented as
means ± SD.
∗P <. 05.
cholesteatoma tissue, however, most NF-κB expression was
observedin thenucleus(activatedform)andwaslocalizedin
all layers of the epithelium (Figure 2(b)). The percentage of
activated NF-κB expression in the cholesteatoma epithelium
was 62.62% ± 18.97% and that in paired normal RA skin
was 5.47% ± 1.12%. The percentage of activated NF-κB
expression in the cholesteatoma epithelium was signiﬁcantly
higher compared to normal RA skin (P =.0001).
3.2. Analysis of the Association between NF-κB and CYLD.
To ﬁnd the association between CYLD and NF-κB, we
examined the correlation between CYLD and activated NF-
κBexpression.Thecalculationswerebasedonthepercentage
of positively stained cells. Using Pearson’s correlation test,
we found a signiﬁcant inverse correlation between CYLD
and activated NF-κB expression in cholesteatoma (Figure 3,
r =− 0.630, P = .007).
3.3. Analysis of Clinical Aspects. Based on the overwhelming
evidence indicating the roles of CYLD and activated NF-κB
in immune regulation, apoptosis, and bone resorption, we
examined whether the expression levels of activated NF-κB
or CYLD are regulated according to clinical aspects, such as
the presence of active otorrhea and state of bony destruction
[6, 9]. The cholesteatoma groups in this study consisted of 6
cases with and 10 cases without active otorrhea at the time of
treatment. We found no signiﬁcant diﬀerences in expression
levels of NF-κB or CYLD between these two groups with and
without active otorrhea (P = .309).
Based on operative ﬁndings, the above patients were
classiﬁed retrospectively into two groups to determine the
extent to which the cholesteatoma destroyed bone; the mild
group had disruption of one ossicle, while the severe group
had widespread bone destruction, including disruption of
more than two ossicles and destruction of the sigmoid sinus,
post wall of the external auditory canal, and the facial
canal. We then compared the expression levels of CYLD and
activatedNF-κB between the two groups. The degree of bone
destruction was mild in 5 cases and severe in 11 cases in this
study. No signiﬁcant relationships were observed between
the degree of bone destruction and the expression levels of
CYLD (P = .769) or activated NF-κB( P = .432).
4. Discussion
CYLD is a tumor suppressor gene mutated in familial
cylindromatosis, also called “turban tumor syndrome,” an
autosomal-dominant condition that confers a predisposition
to multiple skin tumors [1] .T h eg e n ep r o d u c t ,C Y L D ,i sa
DUB recently implicated in the negative regulation of the
NF-κB pathway, a transcription factor suggested to promote
cell proliferation [1, 5]. The present study was performed to
examine the possible role of CYLD expression in the patho-
genesis of cholesteatoma. Speciﬁcally, we were interested in
whether CYLD expression is altered in cholesteatoma and
whether CYLD expression level aﬀects the activity of NF-κB
in cholesteatoma.
The results of the present study indicated that the level
of CYLD expression was signiﬁcantly downregulated in
cholesteatoma in comparison with normal RA skin. The
primary function of DUBs is to remove single or multiple
ubiquitin chains from diﬀerent proteins/substrates. Recently,
diﬀerent speciﬁc substrates for CYLD have been identiﬁed,
suchasTRAF2/6,NEMO,andBcl-3fromwhichCYLDcould
removetheubiquitinchainsbydirectassociation[1,10].The
removal of lysine63-(Lys63-) linked polyubiquitin chains
fromTRAF2orTRAF6byCYLDattenuatesNF-κBsignaling,
leading to programmed cell death [11]. Therefore, loss of the
deubiquitinating activity of CYLD may be correlated with
tumorigenesis.
Recently, reduced CYLD was also found in human carci-
nomas, such as hepatocellular carcinoma and colon cancer,
as compared with nonneoplastic tissue [7]. Moreover, expo-
sure of CYLD knockdown HeLa cells to anti-inﬂammatory
drugs such as sodium salicylate or prostaglandin A1, which
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Figure 2: Immunohistochemistry of NF-κB in cholesteatoma epithelium and normal retroauricular (RA) skin. (a): NF-κBi nn o r m a lR A
skin. (b): NF-κB in cholesteatoma epithelium. Note that strong expression was observed in the nuclei of cells in the basal and suprabasal
layers of cholesteatoma epithelium, whereas weak NF-κB immunoreactivity was mainly seen in the cytoplasm of cells in the basal epithelial
layers of normal RA skin. Bar = 300μm. (c) Rates of positive labeling for NF-κB in the nuclei of cells in cholesteatoma epithelium and
normal RA skin. The rate of cells positive for NF-κB was signiﬁcantly higher in cholesteatoma epithelium than in normal RA skin. Data are
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Figure 3: Analysis of the correlation between CYLD and activated NF-κB in cholesteatoma. (a) The calculations were based on the
immunohistochemical results of the expression rate of cells positive for CYLD and nuclear NF-κB in the serial section. (b) The graph
shows the correlation between CYLD and activated NF-κB in cholesteatoma. The data indicated a signiﬁcant inverse correlation between
CYLD and activated NF-κB expression (Pearson’s correlation test; r =− 0.630, P = .007).
apoptosis, suggesting that loss of CYLD confers resistance
to apoptosis through activation of NF-κB[ 12]. CYLD is
expressed in multiple tissues, but its precise biological
function remains unclear. As noted above, a series of reports
have shown that CYLD blocks signal transmission through
theclassicaloralternativeNF-κBcascadebydeubiquitinating
the TNF receptor-associated factor 2 (TRAF2), TRAF6, and
IKK-γ (NEMO) [1, 5, 6].
However, a recent report showed that the loss of
CYLD in keratinocytes of mice did not aﬀect transcription
induced by the classical p65–p50 NF-κB dimers but had
clear eﬀects on Bcl-3-linked p50- or p52-dependent gene
regulation [10]. Bcl-3 acts as a nuclear coactivator that
switchesthetranscriptionalpropertiesofNF-κBp50andp52
homodimers from a repressive to an active state leading to
cellularproliferationthroughactivationofthecyclinD1gene
[10]. After translocation of Bcl-3 from the cytoplasm to the
perinuclearregion,CYLDremovesK63-linkedpolyubiquitin
chains from Bcl-3, and thus prevents translocation of Bcl-3
into the nucleus [10]. These data suggest that the mechanismMediators of Inﬂammation 5
of CYLD-mediated NF-κBs u p p r e s s i o nm a yv a r yi nd i ﬀerent
cell types.
In the present study, the cytoplasmic and perinuclear
expression levels of CYLD suggest that CYLD may play a
role in the deubiquitination of BCl-3 and/or TRAF in NF-
κB signaling within the cytoplasm or perinuclear region
in keratinocytes of normal skin and cholesteatoma, in
agreement with previously reported results. In addition, the
present ﬁndings suggested that downregulation of CYLD
expression, which is highly expressed in normal skin, may be
involved in the pathogenesis of human cholesteatoma.
The role of NF-κB in epithelial keratinocytes has been
described as being paradoxical in other cell types such as
Tc e l l sa n dBc e l l s[ 13]. For example, mice overexpressing
Rel/p65 NF-κB showed epidermal hypoplasia and growth
inhibition [14], whereas a study on IκBα-null mice showed
epidermal keratinocyte hyperplasia and dermal inﬁltration
of lymphocytes [15]. This variation in outcome of NF-
κB activation may reﬂect the cell types and diﬀerentiation
state of the cells. Lizzul suggested that the antiproliferative
eﬀects of activated NF-κB in normal epithelial cells without
inﬂammationorapoptotic stimulimaybesuperiortoitsanti
apoptotic eﬀects [16].
Activated NF-κB, however, has an anti-apoptotic eﬀect
in proliferative skin disorders such as psoriasis. In normal
murine skin, only basal keratinocytes can proliferate and
diﬀerentiate into mature cells that undergo enucleation to
generate the corniﬁed layer. Therefore, NF-κB is found in
the cytoplasm (inactivated form) of only basal keratinocytes
of normal skin [17]. Our immunohistochemical results of
normal RA skin were in agreement with these ﬁndings.
In the present study, however, signiﬁcant diﬀerences
in NF-κB expression pattern were observed between
cholesteatoma and normal RA skin. In cholesteatoma, strong
immunostaining for NF-κB was seen mostly in the nucleus
and was localized in not only the basal layer but also
the suprabasal layers. This was in contrast to normal RA
skin, which showed NF-κB immunoreactivity mostly in
the cytoplasm of cells in the basal epithelial layers. Some
debate exists regarding the role of NF-κB in cholesteatoma
[2, 3]. The keratinocytes in cholesteatoma are clearly in an
abnormal state, and one would anticipate changes in the
epidermis and keratinocyte. Perhaps, this is why we observed
in contrast control RA skin. That is, cholesteatoma may
represent a chronic inﬂammatory state, and therefore, an
imbalance exists between the anti-apoptotic role and cell
cycle inhibitory role of NF-κB, whereby the scale is tipped
toward protection against cell death in the context of a
constitutive cytokine-rich inﬂammatory milieu. This allows
for the hyperproliferation seen in cholesteatoma.
Therefore, our results suggest that activated NF-κB,
which may provide protection against apoptosis, plays a role
inthepathogenesisofcholesteatoma,unlikenormalRAskin.
Vasudevan reported that the tumor suppressor PTEN, which
functions as a negative regulator of the phosphorylated
Akt-mediated cell survival pathway in cholesteatoma, is
downregulated by activated NF-κB[ 18, 19]. These ﬁndings
also support the results of the present study. To elucidate
the role of CYLD in the expression of activated NF-κBi n
human cholesteatoma, we examined the correlation between
CYLD and activated NF-κB expression in cholesteatoma. We
found a signiﬁcant inverse correlation between CYLD and
NF-κB in cholesteatoma, suggesting that NF-κBa c t i v a t i o n
is inhibited in cases with normal CYLD function but that
it tends to be overexpressed in the absence of functional
CYLD. In addition, our results support the possibility that
NF-κB activation accompanied by loss of CYLD may be an
important step in the development and/or progression of
cholesteatoma. We also examined the relationships between
CYLD/NF-κB and clinical data, such as the presence of
active otorrhea and degree of bone destruction, but no such
relationships were found in the present study. In addition
to the critical role of CYLD in the NF-κB pathway, CYLD
has the ability to function as a negative regulator of the
JNK signaling pathway, which plays an important role in cell
survival in human cholesteatoma. The precise mechanisms
underlying the downregulation of CYLD in cholesteatoma
remain to be elucidated. Nevertheless, our data suggest
the potential role of CYLD inactivation in cholesteatoma
epithelium via multiple mechanisms, ranging from genetic
alteration to epigenetic silencing.
5. Conclusions
We found that CYLD expression was lower and activated
NF-κB expression was higher in cholesteatoma epithelium in
comparison to normal RA skin. These observations suggest
that the activation of NF-κB and downregulation of CYLD
may be involved in the cellular hyperplasia in patients with
cholesteatoma.
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